SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 11:20 AM EDT and participate in one-on-one investor meetings ...

89Bio (ETNB) 2025 Conference May 20, 2025 09:30 AM ET Speaker0 Brian Abraham, senior biotech analyst at RBC Capital Markets. Our next feature company is eighty nine Bio represented by their CEO, Brohan. Thanks so much for joining us. Speaker1 Nice to be here, Brian. Thanks for having us. Speaker2 Kicking things off to set the stage, there's obviously been a Speaker0 lot of developments in the FGF21 space. Speaker2 You guys are one of always been one of the leaders. Speaker0 What's the latest on some of the ...

89Bio (ETNB) 2025 Conference May 14, 2025 01:40 PM ET Speaker0 This joining us on this, our second day of Bank of America's twenty twenty five health care conference here in Las Vegas. My name is Jason Zemanski. I'm one of SMID cap analysts here at the bank, And I'm so pleased to have join me on stage, Rohan Palakkar. Thank you so much for joining us. Speaker1 Great to be here, Jason. Thanks for having us. Well, Speaker0 maybe let's start broadly, especially for those newer to the story. What about FGF21 ma ...

SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in the following investor conferences during the month of May: Annie Chang 89bio, Inc. investors@89bio.com PJ Kelleher LifeSci Advisors, LLC 617-430-7579 pkelleher@lifesciad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4946844 (State or other jurisdiction of incorporation or organization) 655 Montgomery Street, Suite 1500 San F ...

89bio Reports First Quarter 2025 Financial Results and Corporate Updates – Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and m ...

– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $638.8 million as of March 31, 2025; complet ...

We initiate a Buy rating for 89bio, Inc. (NASDAQ: ETNB ), which, in our view, presents a good long-term opportunity, mainly because of its lead candidate, pegozafermin. This drug might be able to help in two challenging indications withAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ETNB over the next 72 hour ...

Company Performance - 89BIO (ETNB) has returned 10.5% year-to-date, outperforming the average gain of 7.4% for Medical stocks [4] - The Zacks Consensus Estimate for ETNB's full-year earnings has increased by 38% over the past quarter, indicating improving analyst sentiment [3] - Eton Pharmaceuticals, Inc. (ETON) has also shown strong performance with a year-to-date return of 13.9% and a consensus EPS estimate increase of 33.8% over the past three months [4][5] Industry Context - 89BIO is part of the Medical - Biomedical and Genetics industry, which consists of 510 companies and currently ranks 66 in the Zacks Industry Rank [6] - The average gain for the Medical - Biomedical and Genetics industry so far this year is 7.8%, with 89BIO outperforming this average [6] - The Medical group, which includes 1012 companies, is currently ranked 3 within the Zacks Sector Rank [2]

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings. The webca ...